LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
Portal Instruments has developed a needle-free jet injector platform to address the increasing needs of patients to self-administer biologics without the need for needles. This simplifies administration, eliminates the need for “sharps containers” in the home, and reduces the time needed to perform self-injections. This technology is particularly timely in light of the increasing use of monoclonal antibodies and therapeutic proteins in drug development. Initially developed by Prof. Ian Hunter’s Group at the Massachusetts Institute of Technology (MIT), the Portal drug administration technology has the potential to transform the way injectable medicines are administered across a wide range of therapeutic indications.
The Portal needle-free system is composed of a re-usable, software-controlled handheld injection device and a proprietary, single-use, pre-filled cartridge. It delivers the medicine through a pressurized liquid jet instead of a needle and has been clinically shown to be less painful and preferred by patients as compared to a standard needle-based injection.1
“LEO Pharma’s novel therapies in the field of medical dermatology combined with Portal’s innovative approach to drug administration offer hope to people living with debilitating skin diseases,” said Christian Antoni, Senior Vice President, Global Development at LEO Pharma. “It is our ambition that this collaboration will lead to new and easier ways for people with skin diseases to administer our treatments on their own in the comfort of their home with a needle-free solution.”
“We are excited at the prospect of working closely with LEO Pharma and support their ambition to empower people with skin diseases with a next-generation drug delivery platform for self-administration,” said Patrick Anquetil, CEO of Portal. “This commercial collaboration gives us the opportunity to lead with innovation in the field of medical dermatology by combining novel medicines with a patient-preferred needle-free drug delivery system.”
[1] Kojic, et al. An Innovative Needle-free Injection System: Comparison to 1 ml Standard, 1 May 2017, AAPS PharmSciTech (# 2017)Contacts
Portal Instruments, Inc
Dr. Patrick Anquetil,
Chief Executive Officer
E-mail: media@portalinstruments.com
LEO Pharma A/S
Maia Fredtoft Soechting,
Corporate Communications Manager
E-mail: mfddk@leo-pharma.com
Tel: +45 2681 4579
About LEO Pharma
About LEO Pharma A/S
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 76 million patients in 130 countries.
For more information, please visit www.leo-pharma.com.
About Portal Instruments, Inc.
Portal Instruments is a venture-backed medical device company, developing and commercializing a connected, needle-free drug delivery platform to transform the administration of medications for chronic diseases. Portal aims to improve the patient experience and outcomes through an innovative needle-free injector with connectivity, analytics, and a companion digital experience. Portal partners with pharmaceutical companies to develop unique drug delivery solutions for their therapies. Its first commercial partnership is with Takeda Pharmaceuticals in the field of Inflammatory Bowel Diseases. Portal Instruments’ Quality Management System is ISO 13485 certified.
For more information, please visit www.portalinstruments.com or follow @portalcambridge on Twitter.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma to present at the 44th annual J.P. Morgan Healthcare Conference7.1.2026 13:00:00 CET | Pressemeddelelse
Ballerup, Denmark, January 7, 2026 – LEO Pharma, a global leader in medical dermatology, announced today that CEO Christophe Bourdon will deliver a company update at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, 2026, at 9:00 AM PST. With over 60 years of specialist expertise in medical dermatology and more than 90 million patients served in 70+ markets, LEO Pharma is uniquely positioned in one of healthcare’s most attractive and underserved sectors. Backed by an unmatched portfolio combining category‑leading brands with first‑in‑class innovations, the company is redefining standards of care for patients with high unmet needs. Entering 2026, LEO Pharma builds on the strong momentum of recent years, marked by robust top-line growth, significant margin expansion, and a promising pipeline. Leveraging its unique global platform, the LEO Pharma is advancing innovation as the preferred partner in medical dermatology. The J.P. Morgan Healthcare Con
LEO Pharma appoints Marika Murto to lead Global Product Strategy16.12.2025 09:00:00 CET | Pressemeddelelse
Marika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growth
LEO Pharma submits adolescent label expansion application for Anzupgo® to EMA15.12.2025 09:00:00 CET | Pressemeddelelse
LEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.
LEO Pharma Announces Positive Topline 32-Week Key Results in ADHAND Trial17.11.2025 09:00:00 CET | Pressemeddelelse
The ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.
LEO Pharma delivers 8% revenue growth at CER in 9M 2025 and updates full-year outlook6.11.2025 09:00:00 CET | Pressemeddelelse
Ballerup, Denmark, 6 November, 2025 - In the first nine months of 2025, LEO Pharma continued its robust revenue growth, with significantly improved profitability and free cash flow. As expected, growth accelerated in the third quarter, with the global rollout of Anzupgo® gaining further momentum after its September launch in the U.S. The 2025 financial outlook is updated to reflect the addition of Spevigo® to the portfolio, reinforcing LEO Pharma’s commitment to advancing innovation and expanding access to care. Highlights LEO Pharma’s revenue increased by 7% to DKK 10,064 million, and by 8% at constant exchange rates (CER), entirely driven by organic growth. The revenue growth was led by North America (+27% at CER), with Europe (+2% at CER) and Rest of World (+6% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 9% (CER), driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 41% (CER), in ad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom